ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Weak Electromagnetic Fields Can Possibly Stabilize Tumors

September 30, 2011

In Brief: Karen Antman And John Glick lead ASCO; ODAC to Meet June 7 On Tamoxifin Trial

May 27, 1994

Cancer Patients Satisfied With Experience In Clinical Trials, Survey Of 2,000 Finds

July 28, 2006

In Brief: Wells, Gardner, Brennan Lead Surgical Oncology; Young, Flynn, Are New officers For Head & Neck

March 26, 1993

DCT Board Oks Recompetition Of Master Agreement For BRM Trials

February 4, 1983

In Brief: Nobel Prize Awarded to Blobel for Research On Protein Signaling; Work Funded By NIH

October 15, 1999